More recently, the ENTRUST-AF PCI trial was reported, in which 1506 patients with AF and PCI for stable CAD or ACS were randomized to dual therapy with edoxaban plus P2Y12 inhibitor or triple therapy with VKA and DAPT [23]. Here, P2RY12 is linked to coronary artery disorder.